Information Library
Results for: White Papers - Faster product development - Phase II/III
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
The Molecular Biomarker Revolution in Non-Small Cell Lung Cancer
June 23, 2011
In this new white paper Quintiles’ experts Christopher Ung, Jason Hill, Carrie Lee and Harish Dave review some of the most promising molecular pathways and targeted approaches for NSCLC, the critical role of diagnostics, and strategies to detect and address the emergence of resistance. -
Oncology Drug Development and Value-Based Medicine
November 5, 2010
This report demonstrates the need to converge clinical and commercial imperatives earlier within the drug development process to meet a future demand for value-based medical practices. -
Pharmacobiomics and Infectious Disease: Progress and Opportunities
November 2, 2010
Pharmacobiomics and Infectious Disease: Progress Opportunities. After decades of work mapping the human genome, we are beginning to reap real benefits. -
From Biomarkers to Diagnostics - The Road to Success
October 18, 2010
In the second installment of a two-part series, Eric Groves, Jason Hill and Christopher Ung walk through the challenges associated with drug-diagnostic co-development, addressing potential pitfalls and areas of opportunity. -
Advancing Clinical Research in Alzheimer's Disease
October 18, 2010
This report from Quintiles’ own Alzheimer’s experts gives you an inside look at the news from ICAD 2010. -
FDA Requirements for Clinical Studies in Pediatric Patients
April 1, 2010
FDA Requirements for Clinical Studies in Pediatric Patients FDA rules around pediatric drug trials have been tightening, to ensure more targeted data on drug efficacy -
Integration of Molecular Biomarkers into Clinical Development
March 29, 2010
Examining the challenges and opportunities in co-developing a biomarker and drug, this is the first white paper in a new series focusing on oncology. -
Regulations for Clinical Studies in Pediatric Patients in the European Union
March 10, 2010
After the United States issued pediatric drug study requirements, the European Union (EU) passed a regulation that created major changes to clinical studies for pediatric -
Key Trends in Multiple Myeloma Treatment
February 26, 2010
An overview of the latest studies into novel drug combinations and new therapies in early stage testing in multiple myeloma. -
Biomarker Trends in Breast Cancer Research
February 24, 2010
Dr. Hill discusses the implications and questions that will drive future R&D efforts to develop targeted breast cancer therapies.
